Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for shareholders to make money if they buy a good busines ...

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

The latest update is out from Inmune Bio ( (INMB) ).

Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Inmune Bio ( (INMB) ) just unveiled an update.

Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...

In addition to the Alzheimer's study, INmune Bio's INKmune memory-like natural killer cell oncology platform has also reported significant progress. The company's recent direct offering secured ...

In light of INmune Bio Inc.'s recent stock performance, InvestingPro data and insights offer a deeper look into the company's financial health and market position. As of the last twelve months leading ...

Company News Published 09/20/2024, 11:14 AM 0 INmune Bio stock hits 52-week low at $5.17 amid market challenges INMB 5.39% ...

On September 12, 2024, Moss purchased 7,690 shares of Inmune Bio's common stock at a price of $6.375 per share, amounting to a total investment of $49,023.

INMUNE BIO Hedge Fund Activity We have seen 46 institutional investors add shares of INMUNE BIO stock to their portfolio, and 19 decrease their positions in their most recent quarter.